CARY, N.C., Oct. 20, 2021 -- Two North Carolina companies, analytics leader SAS and venture investment firm Pappas Capital, are joining forces to help advance the state as a global...
Biovitrum and Syntonix set to begin Phase 1/2a clinical trial for the treatment of Hemophilia B
News | 03. 04. 2008
Syntonix Pharmaceuticals
Biovitrum AB (publ), Sweden, and Syntonix Pharmaceuticals, Inc., USA, have obtained approval from the US Food and Drug Administration to commence a clinical phase I/IIa study of a long-acting, recombinant Factor IXFc for the treatment of Hemophilia B.
